Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | FNTA | P49354 | 1/20 | 0.69 |
| ▸ | FNTB | P49356 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole-3-Acetic Acid SCHEMBL26344 | 0.98 | MEN1 (0.75) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL7887240 | 0.98 | MEN1 (0.75) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL29350750 | 0.98 | MEN1 (0.75) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL1375190 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL29272696 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL29272533 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL11125791 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL31084632 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL31152574 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL29712109 | 0.96 | MEN1 (0.73) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | TUSKEGEE UNIVERSITY (US) | 2015-06-18 | — | — | US | claimed |
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-05-03 | — | — | US | claimed |
| CN-102438453-A | Plant growth regulator additive | TAMINCO NV | 2012-05-02 | — | — | CN | claimed |
| EP-2416653-A2 | PLANT GROWTH REGULATOR ADDITIVE | Taminco, Naamloze Vennootschap (BE) | 2012-02-15 | — | — | EP | claimed |
| WO-2010116259-A2 | PLANT GROWTH REGULATOR ADDITIVE | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2010-10-14 | — | — | WO | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| CN-118077821-A | Immunoregulation and growth promotion composition for improving intestinal strains of animals and application thereof | 中国农业大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-118000310-A | Feed for improving weaning stress of piglets and improving intestinal health and application of feed | 中国农业大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-114681492-B | Intestinal probiotics for improving metabolic diseases and application thereof | 中国科学院上海营养与健康研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11859248-B2 | Nucleic acid modification and identification method | IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2024-01-02 | — | — | US | disclosed |
| CN-110520540-B | Nucleic acid modification and identification method | IMBA-莫利库尔生物技术研究所 | 2023-10-03 | — | — | CN | disclosed |
| US-20230175033-A1 | PRODUCTION OF JASMONATES IN FILAMENTOUS FUNGI | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-06-08 | — | — | US | disclosed |
| WO-2023101458-A1 | COMPOSITION FOR PROMOTING CTCF-MEDIATED TRANSCRIPT CONDENSATION | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | disclosed |
| CN-1568370-A | treatment of central nervous system disorders with D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET SA (FR) | 2005-01-19 | — | — | CN | disclosed |
| EP-1412515-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | Genset (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2003047558-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS | GENSET S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | MEN1 3939/4885KMT2A 2219/4885MAPT 460/4885 |
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | MCL1, BAD, API5 | MEN1 2451/4885KMT2A 1698/4885MAPT 4347/4885 |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | MEN1 3939/4885KMT2A 2219/4885MAPT 460/4885 |
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | MYB, ING2, AGXT | MEN1 4545/4885KMT2A 710/4885MAPT 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.